All In Biotech

Drug Trial Radar · NCT02378480

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Last checked: Nov 20, 2026Latest source record: Mar 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 655 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

655

Actual

Start

Jun 2015

Primary completion

Apr 2016

Study completion May 2016

Sponsor

Lead sponsor
Paratek Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Mar 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.

Conditions

  • Bacterial Infections
  • Skin Structures and Soft Tissue Infections

Interventions

  • OmadacyclineDrug

    Injection for IV dosing; Tablets for oral dosing

  • LinezolidDrug

    Infusion solution for IV dosing; Tablets for oral dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Early Clinical ResponseTime frame: Screening; 48 to 72 hours after the first dose of test article

Locations

78 sites in 14 countries. Site status is shown where the registry gives one.

  • Site 261

    Mobile, Alabama

  • Site 262

    Chula Vista, California

  • Site 254

    La Mesa, California

  • Site 258

    Oceanside, California

  • Site 252

    Santa Ana, California

  • Site 260

    Santa Ana, California

  • Site 269

    Stockton, California

  • Site 259

    Miami, Florida

  • Site 264

    West Palm Beach, Florida

  • Site 256

    Augusta, Georgia

  • Site 253

    Columbus, Georgia

  • Site 257

    Springfield, Massachusetts

  • Site 268

    Detroit, Michigan

  • Site 266

    Butte, Montana

  • Site 263

    Las Vegas, Nevada

  • Site 270

    Somers Point, New Jersey

  • Site 273

    Buffalo, New York

  • Site 255

    Rapid City, South Dakota

  • Site 104

    Pleven, Bulgaria

  • Site 102

    Plovdiv, Bulgaria

  • Site 105

    Plovdiv, Bulgaria

  • Site 103

    Rousse, Bulgaria

  • Site 101

    Sofia, Bulgaria

  • Site 205

    Slavonski Brod, Croatia

  • Site 201

    Zagreb, Croatia

  • Site 203

    Zagreb, Croatia

  • Site 202

    Zagreb, Croatia

  • Site 204

    Zagreb, Croatia

  • Site 207

    Athens, Greece

  • Site 211

    Athens, Greece

  • Site 208

    Thessaloniki, Greece

  • Site 209

    Thessaloniki, Greece

  • Site 110

    Budapest, Hungary

  • Site 111

    Budapest, Hungary

  • Site 114

    Miskolc, Hungary

  • Site 113

    Szeged, Hungary

  • Site 213

    Holon, Israel

  • Site 219

    Kfar Saba, Israel

  • Site 214

    Nazareth, Israel

  • Site 216

    Safed, Israel

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.